11 July 2025 - The Federal Ministers give a final decision (positive with conditions) for this trial
Trial reference:
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B